Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status.
ERG
Grade groups
Mismatch repair genes
PTEN
Prostate cancer
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
27
12
2018
accepted:
03
06
2019
revised:
05
04
2019
pubmed:
19
6
2019
medline:
28
7
2019
entrez:
19
6
2019
Statut:
ppublish
Résumé
The role of DNA MMR genes in prostate cancer (PrCa) is controversial, as genetic alterations leading to microsatellite instability are incompletely defined in these tumors. ERG rearrangements and PTEN loss are concomitant events in PrCa. The aim of this study has been to analyze the immunohistochemical (IHC) expression of MSH2, MSH6, MLH1, PMS2, ERG, and PTEN and their potential association with the grade group (GG) grading system (WHO 2016) and PSA recurrence in a series of 200 PrCa (PSMAR-Biobank, Barcelona, Spain). MSH2, MLH1, PMS2, and PTEN losses were documented in 8%, 5%, 2%, and 36.5%, respectively. ERG expression was found in 48%. MSH6 showed an increase of expression with respect to basal levels in 42.1% of the cases. A statistical association between MSH6 overexpression and GG5 was found (p = 0.0281). ERG-wild-type cases were associated with single MSH2 loss (p = 0.024), and MSH2 and/or MLH1 loss (p = 0.019). The percentage of cases with PTEN loss was 20.5% (8/39) in GG1, 37.6% (53/141) of clustered GG2 to 4, and 60% (12/20) of GG5 (chi-square test, p = 0.01). Thus, PTEN expression loss was statistically more frequent in the upper-grade tumors. PMS2 loss was an infrequent event, but it was statistically associated with shorter time to PSA recurrence (p = 0.011). These results suggest the existence of an alternative non-ERG pathway associated with MSH2 or MLH1 expression loss. MSH6 overexpression could be a marker of aggressiveness in PrCa. The IHC assessment of DNA MMR proteins, ERG and PTEN, could identify different altered PrCa pathways, which could aid patient stratification.
Identifiants
pubmed: 31209634
doi: 10.1007/s00428-019-02591-z
pii: 10.1007/s00428-019-02591-z
doi:
Substances chimiques
Biomarkers, Tumor
0
ERG protein, human
0
Transcriptional Regulator ERG
0
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Langues
eng
Pagination
223-231Références
Curr Opin Genet Dev. 1999 Feb;9(1):89-96
pubmed: 10072354
Science. 2001 Feb 16;291(5507):1284-9
pubmed: 11181991
Cancer Res. 2001 May 15;61(10):4112-21
pubmed: 11358834
Cancer. 2002 Feb 1;94(3):690-9
pubmed: 11857301
Cancer Biol Ther. 2002 Jul-Aug;1(4):362-7
pubmed: 12432247
J Neurooncol. 2004 Jan;66(1-2):51-7
pubmed: 15015769
Am J Surg Pathol. 2005 Jan;29(1):96-104
pubmed: 15613860
Science. 2005 Oct 28;310(5748):644-8
pubmed: 16254181
J Mol Med (Berl). 2006 Oct;84(10):833-41
pubmed: 16924473
Prostate. 2007 Feb 1;67(2):214-25
pubmed: 17044039
Cell Res. 2008 Jan;18(1):85-98
pubmed: 18157157
Oncol Rep. 2008 Feb;19(2):401-6
pubmed: 18202787
Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):57-64
pubmed: 19124481
Nat Genet. 2009 May;41(5):524-6
pubmed: 19396167
Nat Genet. 2009 May;41(5):619-24
pubmed: 19396168
Mod Pathol. 2009 Aug;22(8):1083-93
pubmed: 19407851
Eur Urol. 2009 Aug;56(2):275-86
pubmed: 19409690
Nat Rev Urol. 2009 Aug;6(8):429-39
pubmed: 19657377
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):258-64
pubmed: 20056646
Mod Pathol. 2010 Apr;23(4):539-46
pubmed: 20118910
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Nature. 2011 Feb 10;470(7333):214-20
pubmed: 21307934
Clin Cancer Res. 2011 Oct 15;17(20):6563-73
pubmed: 21878536
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Mod Pathol. 2013 Mar;26(3):435-47
pubmed: 23018874
J Clin Oncol. 2013 May 10;31(14):1782-4
pubmed: 23530097
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):209-15
pubmed: 23545904
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
PLoS One. 2013 Oct 24;8(10):e78500
pubmed: 24205245
Mod Pathol. 2014 Dec;27(12):1612-20
pubmed: 24762546
Nat Commun. 2014 Sep 25;5:4988
pubmed: 25255306
PLoS One. 2015 May 04;10(5):e0125560
pubmed: 25938433
Prostate. 2015 Aug 1;75(11):1216-26
pubmed: 25939480
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Prostate. 2016 Jun;76(9):854-65
pubmed: 26959281
Carcinogenesis. 2017 Jan;38(1):19-27
pubmed: 27803051
Nature. 2016 Nov 24;539(7630):583-587
pubmed: 27851738
Clin Cancer Res. 2017 Nov 15;23(22):6863-6874
pubmed: 28790115
Oncotarget. 2017 May 26;8(43):74106-74118
pubmed: 29088771